Clinical trials: Substance Abuse, Intravenous
- Condition Substance Abuse, Intravenous
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Hepatitis C, Chronic, Substance Abuse, Intravenous
Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261)
Previous intravenous drug abusers with chronic hepatitis C who are under substitution therapy (buprenorphine, methadone) will be treated with PegIntron and Rebetol according to the approved European labeling.
- Trial name
- SUPPORT (NCT00726557)
- Testing
- PegIntron (pegylated interferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 246 people
- Sponsor
- Merck Sharp & Dohme LLC
Substance Use Disorders, Methamphetamine Abuse
A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants
The purpose of this Phase 1a study is to evaluate safety, tolerability, and pharmacokinetics (PK) of single, ascending doses of CS-1103, administered by intravenous (IV) infusion in healthy participants.
- Conditions
- Substance Use Disorders, Methamphetamine Abuse, Methamphetamine Intoxication
- Trial name
- NCT06316973
- Testing
- CS-1103, Sterile Saline
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Clear Scientific, Inc.